MDT-BRIDGE Trial

[Slide 1] IASLC 2026 World Conference on Lung Cancer I F SEPTEMBER 12 - 15, 2026 I SEOUL, REPUBLIC OF KOREA KALC SCIENCE WITHOUT BOUNDARIES: UNITING THE WORLD AGAINST THORACIC CANCER --- [Slide 2] IASLC 2026 World Conference SEPTEMBER 12 - 15, 2026 07 min 29s on Lung Cancer SEOUL, REPUBLIC OF KOREA MDT-BRIDGE study design Global, non-randomized, phase 2 study Adjuvant/ Neoadjuvant period A Neoadjuvant period B consolidation period Durvalumab + MDT Surgery Baseline MDT Resectable⁺ investigator's choice Durvalumab + reassessment Durvalumab resectability of platinum-based CT investigator's choice Restaging/ monotherapy assessment* Q3W for 1-2 cycles of platinum-based CT optional Q4W for 12 cycles (resectable or Q3W for 2 cycles pathologic borderline resectable) confirmation CRT Unresectable Key inclusion criteria and study requirements Primary endpoint Aged ≥18 years Resection rate, defined as proportion of all patients (FAS) who underwent definitive surgery Previously untreated Secondary endpoints Pathologically confirmed, resectable or borderline Resection rate in patients deemed resectable/borderline resectable at baseline resectable stage IIB-IIIB NSCLC (AJCC 8th edition¹) Surgical outcomes in patients who underwent surgery EGFR/ALK wild type (per local test) ORR in patients deemed resectable/unresectable at MDT reassessment WHO/ECOG PS 0-1 pCR and EFS in all patients (FAS) and patients deemed resectable at MDT reassessment At least 1 target lesion not previously irradiated PFS in patients deemed unresectable at MDT reassessment Pre-operative RT not allowed Safety *MDT comprised a medical/pulmonary oncologist, thoracic surgeon, radiation oncologist, and pathologist at a minimum; resectable/borderline resectable status determined per MDT decision based on baseline available assessments. Patients who were deemed eligible for surgery at MDT evaluation but then deemed unresectable/progressed locally at the pre-surgery assessments entered the unresectable cohort. Five fractions/week for ~6 weeks (± 3 days) (total 60 Gy + 10%). Efficacy outcomes are reported, unless otherwise indicated, according to prespecified analysis populations except for pCR (assessed per local pathology review), which was not prespecified for analysis in all patients. AJCC, American Joint Committee on Cancer; ECOG, Eastern Cooperative Oncology Group; FAS, full analysis set (i.e., all patients who received at least one dose of study intervention); Gy, gray; ORR, objective response rate; PS, performance status; QXW, once every X weeks; RT, radiotherapy; WHO, World Health Organization. 1. Amin MB, et al. AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2017. --- [Slide 3] IASLC 2026 World Conference SEPTEMBER 12 - 15, 2026 05 min 25s 2026 on Lung Cancer SEOUL, REPUBLIC OF KOREA Resection rates and outcomes (FAS) The overall resection rate was 74.6% and most patients had R0 resection 100 Resection rate, 80 % (95% CI)*,⁺ 60 40 20 74.6% 81.5% 62.0% (66.7-81.6) (72.1-88.9) (47.2-75.3) 0 All patients Resectable Borderline resectable (N=142) at baseline (n=92) at baseline (n=50) 2.8% 0.9% 4.0% 3.2% (0.6-8.0) (0.0-5.1) (0.8-11.2) 0% (0.1-16.7) (0.0-4.8) 0% Resection (0.0-11.2) outcomes, % (95% CI)* 96.2% 96.0% 96.8% (90.6-99.0) (88.8-99.2) (83.3-99.9) R0 R1 R2 R0 R1 R2 R0 R1 R2 Resected cohort: all patients Resected cohort: resectable at Resected cohort: borderline (n=106) baseline (n=75) resectable at baseline (n=31) DCO, 12 January 2026. *Defined as the proportion of patients who started resection. Cls calculated by Clopper-Pearson exact method. Percentages based on the number of patients who started resection surgery as the denominator. CI, confidence interval. 9 --- [Slide 4] IASLC 2026 World Conference SEPTEMBER 12 - 15, 2026 03 min 37s on Lung Cancer SEOUL, REPUBLIC OF KOREA pCR EFS by pCR 27.3% of all patients resectable at MDT 12-month EFS was higher in patients with vs reassessment had pCR, including 31.3% without pCR (100% VS 89.8%) who were resectable at baseline Resectable at pCR No pCR MDT reassessment No. events / no. patients (%) 0/33 (0) 9/73 (12.3) 12-month EFS, % (95% CI)* 100.0 (100.0-100.0) 89.8 (79.6-95.0) 30 1.00 FAS 0.75 pCR rate, % (95% CI)* 20 Probability of EFS 0.50 10 0.25 23.2% 31.3% 18.4% 27.3% 0.00 (16.6-31.1) (21.6-42.4) (7.7-34.3) (19.6-36.1) 0 3 6 9 12 15 18 21 0 All patients Resectable Borderline Resectable No. at risk: Time from first dose (months) (N=142) at baseline resectable at cohort pCR 33 33 30 19 10 0 0 0 (n=83) baseline (n=121) No pCR 73 73 64 50 30 5 3 0 (n=38) DCO, 12 January 2026. *95% Cls calculated by Clopper-Pearson exact method. Median follow-up (range) in censored patients with VS without pCR: 10.4 (5.3-14.1) VS 11.4 (4.6-20.2) months. 13 ***

[Slide 1] IASLC 2026 World Conference SEPTEMBER 12 - 15, 2026 08 min 35s on Lung Cancer SEOUL, REPUBLIC OF KOREA MDT-BRIDGE study design Global, non-randomized, phase 2 study Adjuvant/ Neoadjuvant period A Neoadjuvant period B consolidation period Durvalumab + MDT Surgery Baseline MDT Resectable+ investigator's choice Durvalumab + reassessment Durvalumab resectability of platinum-based CT investigator's choice Restaging/ monotherapy assessment* Q3W for 1-2 cycles of platinum-based CT optional Q4W for 12 cycles (resectable or Q3W for 2 cycles pathologic borderline resectable) confirmation CRT Unresectable Key inclusion criteria and study requirements Primary endpoint Aged ≥18 years Resection rate, defined as proportion of all patients (FAS) who underwent definitive surgery Previously untreated Secondary endpoints Pathologically confirmed, resectable or borderline Resection rate in patients deemed resectable/borderline resectable at baseline resectable stage IIB-IIIB NSCLC (AJCC 8th edition¹) Surgical outcomes in patients who underwent surgery EGFR/ALK wild type (per local test) ORR in patients deemed resectable/unresectable at MDT reassessment WHO/ECOG PS 0-1 pCR and EFS in all patients (FAS) and patients deemed resectable at MDT reassessment At least 1 target lesion not previously irradiated PFS in patients deemed unresectable at MDT reassessment Pre-operative RT not allowed Safety *MDT comprised a medical/pulmonary oncologist, thoracic surgeon, radiation oncologist, and pathologist at a minimum; resectable/borderline resectable status determined per MDT decision based on baseline available assessments. Patients who were deemed eligible for surgery at MDT evaluation but then deemed unresectable/progressed locally at the pre-surgery assessments entered the unresectable cohort. Five fractions/week for ~6 weeks (± 3 days) (total 60 Gy ± 10%). Efficacy outcomes are reported, unless otherwise indicated, according to prespecified analysis populations except for pCR (assessed per local pathology review), which was not prespecified for analysis in all patients. AJCC, American Joint Committee on Cancer; ECOG, Eastern Cooperative Oncology Group; FAS, full analysis set (i.e., all patients who received at least one dose of study intervention); Gy, gray; ORR, objective response rate; PS, performance status; QXW, once every X weeks; RT, radiotherapy; WHO, World Health Organization. 1. Amin MB, et al. AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2017. --- [Slide 2] IASLC 2026 World Conference SEPTEMBER 12 - 15, 2026 05 min 49s 2026 on Lung Cancer SEOUL, REPUBLIC OF KOREA Changes in resectability assessments and local treatment (FAS) After 2 cycles of neoadjuvant durvalumab + CT, most patients, including those who were borderline resectable at baseline, were deemed resectable at MDT reassessment MDT reassessment, Adjuvant or consolidation Baseline MDT Local Tx durvalumab post cycle 2* assessment Resected 94 Adjuvant Tx 82 Resectable 92 120 106 Yi 106+ 12 38 12 No adjuvant Tx 7 Borderline CRT 50 23 23 Consolidation Tx resectable 25 7 9 2 2 No consolidation Tx 18 11 No local Tx Unresectable 1 20 2 11 cCRT: 21 sCRT: 4 1 2 Not reassessed 2 92.3% had either surgery or CRT after neoadjuvant durvalumab + CT DCO, 12 January 2026. *Two patients discontinued and were not reassessed: one deemed resectable and one deemed borderline resectable at baseline. The patient who was resectable at baseline was included in the 'Resectable' cohort and the patient who was borderline resectable at baseline was included in the 'Unresectable' cohort, as prespecified in the statistical analysis plan. Two patients did not complete surgical resection as intended due to the absence of primary tumor in the lung parenchyma; only lymph nodes were removed. c/sCRT, concurrent/sequential CRT; Tx, treatment. Summaries of MDT assessment cohorts and local treatment available via OR code. --- [Slide 3] IASLC 2026 World Conference SEPTEMBER 12 - 15, 2026 06 min 22s 2026 on Lung Cancer SEOUL, REPUBLIC OF KOREA Reasons for borderline resectability status at baseline (FAS) Tumor T and/or N status primarily drove borderline resectability assessment at baseline, and R0 resection was uncertain in approximately one-quarter of these patients Criteria leading to borderline resectability MDT assessment of the potential for R0 resection 60 assessment at baseline (n=50)⁺ before neoadjuvant treatment Resectable Borderline resectable 50 at baseline (n=92) at baseline (n=50) 3,3% Proportion of patients, % 40 28,0% 30 50,0% 72,0% 96,7% 20 32,0% 10 8,0% 6,0% 4,0% R0 possible R0 uncertain 0 Only T Only N Both T and Neither T or Missing status status N status N status DCO, 12 January 2026. *As reported by the MDT or investigators. Percentages calculated based on the number of patients deemed borderline resectable at baseline as the denominator. 7 --- [Slide 4] IASLC 2026 World Conference SEPTEMBER 12 - 15, 2026 04 min 05s 2026 on Lung Cancer SEOUL, REPUBLIC OF KOREA EFS and PFS in subgroups of interest EFS in patients resectable at MDT PFS in patients unresectable at MDT reassessment and in resected patients reassessment and in CRT-treated patients Resectable Resected Unresectable CRT-treated No. events / no. patients (%) 15/121 (12.4) 9/106 (8.5) No. events / no. patients (%) 5/21 (23.8) 6/25 (24.0) 12-month EFS, % (95% CI)* 90.1 (82.8-94.4) 92.9 (85.5-96.6) 12-month PFS, % (95% CI)** 75.1 (45.2-90.2) 85.0 (59.8-95.0) 1.00 1.00 Probability of EFS 0.75 0.75 0.50 Probability of PFS 0.50 0.25 0.25 0.00 0.00 0 3 6 9 12 15 18 21 0 3 6 9 12 15 18 No. at risk: Time from first dose (months) No. at risk: Time from first dose (months) Resectable 121 117 101 75 43 5 3 0 Unresectable 21 18 12 8 5 1 0 Resected 106 106 94 69 40 5 3 0 CRT-treated 25 22 17 12 8 1 0 DCO, 12 January 2026. *12-month rate calculated by Kaplan-Meier method, with 95% Cls calculated by Brookmeyer-Crowley method. Based on 23.8% maturity and median PFS follow-up of 7.3 months in all (censored) patients deemed unresectable at reassessment, with PFS defined as the time from the first dose of any study treatment until PD, assessed by the investigator per RECIST version 1.1, or death (by any cause in the absence of progression) regardless of whether the patient withdrew from therapy or received another anticancer therapy prior to progression. ORR at pre-surgery/pre-CRT available via OR code. 12 00 ...